REPORTS

Let’s Pullulate and Expand Your Business

Chimeric Antigen Receptor (CAR) T-Cell Therapy Market - Global Professional Analysis and Forecast to 2026

Oct 15, 2019  |  173 PAGES  |  REPORT CODE: CMM210889
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Chimeric Antigen Receptor (CAR) T-Cell Therapy market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 2.7% during the forecast period.

This report presents the market size and development trends by detailing the Chimeric Antigen Receptor (CAR) T-Cell Therapy market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Chimeric Antigen Receptor (CAR) T-Cell Therapy market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Chimeric Antigen Receptor (CAR) T-Cell Therapy industry and will help you to build a panoramic view of the industrial development.

Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, By Type:

  • Acute Lymphoblastic Leukemia (ALL)

  • Advanced Lymphomas

  • Others

Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, By Application:

  • Children

  • Adult

Some of the leading players are as follows:

  • Gilead Sciences

  • Cellectis

  • Novartis AG

  • Protheragen Inc.

  • F. Hoffman La Roche AG

  • iCell Gene Therapeutics

  • Puretech Health

  • Editas Medicine Inc.

  • Amgen

  • Transgene SA

  • Juno Therapeutics Inc. (A Celgene Company)

  • Shire Pharmaceuticals Inc.

  • Formula Pharmaceuticals Inc.

  • Avacta Life Sciences Ltd.

  • Bellicum Phamaceuticals

  • Takeda Pharmaceuticals

  • Medimmune Llc/Astrazeneca

  • Bluebird Bio

  • Kite Pharma Inc. (A Subsidiary of Gilead Sciences Inc.)

  • Celyad SA

  • Servier Laboratories

  • Eureka Therapeutics Inc.

  • Celgene Corp.

  • Mustang Bio Inc.

  • Noile-Immune Biotech

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Technology Type Analysis

  • 4.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Acute Lymphoblastic Leukemia (ALL)

    • 4.3.2 Advanced Lymphomas

    • 4.3.3 Others

5 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Product Analysis

  • 5.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Market Share Analysis, 2018 & 2026

  • 5.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Application Analysis

  • 6.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Application Market Share Analysis, 2018 & 2026

  • 6.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Children

    • 6.3.2 Adult

7 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Regional Analysis

  • 7.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Regional Market Share Analysis, 2018 & 2026

  • 7.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Gilead Sciences

    • 9.1.1 Gilead Sciences Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Cellectis

    • 9.2.1 Cellectis Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Novartis AG

    • 9.3.1 Novartis AG Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Protheragen Inc.

    • 9.4.1 Protheragen Inc. Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 F. Hoffman La Roche AG

    • 9.5.1 F. Hoffman La Roche AG Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 iCell Gene Therapeutics

    • 9.6.1 iCell Gene Therapeutics Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Puretech Health

    • 9.7.1 Puretech Health Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Editas Medicine Inc.

    • 9.8.1 Editas Medicine Inc. Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Amgen

    • 9.9.1 Amgen Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Transgene SA

    • 9.10.1 Transgene SA Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Juno Therapeutics Inc. (A Celgene Company)

    • 9.11.1 Juno Therapeutics Inc. (A Celgene Company) Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Shire Pharmaceuticals Inc.

    • 9.12.1 Shire Pharmaceuticals Inc. Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 Formula Pharmaceuticals Inc.

    • 9.13.1 Formula Pharmaceuticals Inc. Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 Avacta Life Sciences Ltd.

    • 9.14.1 Avacta Life Sciences Ltd. Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 Bellicum Phamaceuticals

    • 9.15.1 Bellicum Phamaceuticals Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

  • 9.16 Takeda Pharmaceuticals

    • 9.16.1 Takeda Pharmaceuticals Company overview

    • 9.16.2 Financial performance

    • 9.16.3 Product benchmarking

    • 9.16.4 Strategic initiatives

    • 9.16.5 SWOT analysis

  • 9.17 Medimmune Llc/Astrazeneca

    • 9.17.1 Medimmune Llc/Astrazeneca Company overview

    • 9.17.2 Financial performance

    • 9.17.3 Product benchmarking

    • 9.17.4 Strategic initiatives

    • 9.17.5 SWOT analysis

  • 9.18 Bluebird Bio

    • 9.18.1 Bluebird Bio Company overview

    • 9.18.2 Financial performance

    • 9.18.3 Product benchmarking

    • 9.18.4 Strategic initiatives

    • 9.18.5 SWOT analysis

  • 9.19 Kite Pharma Inc. (A Subsidiary of Gilead Sciences Inc.)

    • 9.19.1 Kite Pharma Inc. (A Subsidiary of Gilead Sciences Inc.) Company overview

    • 9.19.2 Financial performance

    • 9.19.3 Product benchmarking

    • 9.19.4 Strategic initiatives

    • 9.19.5 SWOT analysis

  • 9.20 Celyad SA

    • 9.20.1 Celyad SA Company overview

    • 9.20.2 Financial performance

    • 9.20.3 Product benchmarking

    • 9.20.4 Strategic initiatives

    • 9.20.5 SWOT analysis

  • 9.21 Servier Laboratories

    • 9.21.1 Servier Laboratories Company overview

    • 9.21.2 Financial performance

    • 9.21.3 Product benchmarking

    • 9.21.4 Strategic initiatives

    • 9.21.5 SWOT analysis

  • 9.22 Eureka Therapeutics Inc.

    • 9.22.1 Eureka Therapeutics Inc. Company overview

    • 9.22.2 Financial performance

    • 9.22.3 Product benchmarking

    • 9.22.4 Strategic initiatives

    • 9.22.5 SWOT analysis

  • 9.23 Celgene Corp.

    • 9.23.1 Celgene Corp. Company overview

    • 9.23.2 Financial performance

    • 9.23.3 Product benchmarking

    • 9.23.4 Strategic initiatives

    • 9.23.5 SWOT analysis

  • 9.24 Mustang Bio Inc.

    • 9.24.1 Mustang Bio Inc. Company overview

    • 9.24.2 Financial performance

    • 9.24.3 Product benchmarking

    • 9.24.4 Strategic initiatives

    • 9.24.5 SWOT analysis

  • 9.25 Noile-Immune Biotech

    • 9.25.1 Noile-Immune Biotech Company overview

    • 9.25.2 Financial performance

    • 9.25.3 Product benchmarking

    • 9.25.4 Strategic initiatives

    • 9.25.5 SWOT analysis

 

The List of Tables and Figures (Totals 94 Figures and 161 Tables)

  • Figure Acute Lymphoblastic Leukemia (ALL) Chimeric Antigen Receptor (CAR) T-Cell Therapy market, 2015 - 2026 (USD Million)

  • Figure Advanced Lymphomas Chimeric Antigen Receptor (CAR) T-Cell Therapy market, 2015 - 2026 (USD Million)

  • Figure Others Chimeric Antigen Receptor (CAR) T-Cell Therapy market, 2015 - 2026 (USD Million)

  • Figure Children market, 2015 - 2026 (USD Million)

  • Figure Adult market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by country, 2015 - 2026 (USD Million)

  • Table North America Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table North America Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table North America Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by country, 2015 - 2026 (USD Million)

  • Table Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table France Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table France Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table Spain Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table Spain Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table China Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table China Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table India Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table India Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by country, 2015 - 2026 (USD Million)

  • Table MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Chimeric Antigen Receptor (CAR) T-Cell Therapy market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Gilead Sciences Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Cellectis Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novartis AG Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Protheragen Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table F. Hoffman La Roche AG Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table iCell Gene Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Puretech Health Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Editas Medicine Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Amgen Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Transgene SA Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Juno Therapeutics Inc. (A Celgene Company) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Shire Pharmaceuticals Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Formula Pharmaceuticals Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Avacta Life Sciences Ltd. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bellicum Phamaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Takeda Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Medimmune Llc/Astrazeneca Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bluebird Bio Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Kite Pharma Inc. (A Subsidiary of Gilead Sciences Inc.) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Celyad SA Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Servier Laboratories Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Eureka Therapeutics Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Celgene Corp. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Mustang Bio Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Noile-Immune Biotech Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$4840
$9680
BUY NOWClick MeBUY NOW
top